Whalesbook
Oil Shock Ne Market Ko Hilaya
Aaj Indian equity markets mein bhari girawat dekhne ko mili. Benchmark Sensex index 1,100 points se zyada fisla, aur Nifty 50 bhi 23,820 ke neeche chala gaya. Is badi sell-off ka reason global tensions hain, jinki wajah se Brent crude oil $125 per barrel cross kar gaya. Strait of Hormuz mein supply chain disruption ke darr ne oil price ko aur badha diya. Aise mein, India jaise oil import karne wale countries par kaafi pressure aa jata hai, aur investors risk kam karne lagte hain.
Is sabka asar Indian Rupee par bhi dikha, jo US dollar ke saamne record low 95.27 par aa gaya. Foreign investors bhi paisa nikaal rahe hain aur oil import ka kharcha badh gaya hai, isliye Rupee kamzor hua. Yeh market ki sensitivity dikhata hai global stability aur commodity prices ko lekar.
AI Boom Aur Badi Deals Ne Kiya Dhyan Attract
Jab market mein yeh sab chal raha tha, tabhi artificial intelligence (AI) sector mein valuations ki baat ho rahi thi. Sunne mein aa raha hai ki Anthropic PBC $900 billion se zyada valuation par funding explore kar raha hai. Yeh valuation uske competitor OpenAI se kaafi zyada hai, jiska valuation $80-100 billion ke aas paas hai.
Companies ne bhi deals mein interest dikhaya. Renault India ne NCLT se apni operations ko restructure karne ki permission mangi hai, taaki structure simple ho aur exports badh sakein. Aur ek badi khabar ye hai ki Sun Pharmaceutical Industries ne apni sabse badi acquisition ki hai, Organon ko $11.75 billion mein kharidne ka deal pakka kiya hai. Yeh deal khaas hai kyunki Sun Pharma founder Dilip Shanghvi ne pehli baar major acquisition ke liye debt financing ka use kiya hai.
Aur kya? India ke ETFs (Exchange Traded Funds) ne fiscal year 2026 mein record ₹1.81 lakh crore ka inflow record kiya hai. Ismein commodity-focused ETFs ne equity ETFs se behtar perform kiya, jo dikhata hai ki investors inflation aur market volatility ke khilaaf hedge karne wale assets ki taraf shift ho rahe hain.
Underlying Risks Bhi Hain
AI aur pharma deals mein positivity ke bawajood, kuch risks bhi hain. Sun Pharma ki $11.75 billion ki deal se debt badh gaya hai, jisse loan payments manage karne mein dikkat aa sakti hai, khaas kar agar market conditions kharab hui toh. Wahi, Renault India ko market mein apna share badhane mein hamesha dikkat aayi hai, toh unka restructuring plan kitna successful hoga, yeh dekhna hoga.
RBI ka naya Expected Credit Loss (ECL) framework, jo April 1, 2027 se apply hoga, banking sector ke liye challenging ho sakta hai. Isse banks ko zyada provisioning karni pad sakti hai, jo unke profits ko affect kar sakta hai. Chhote banks par iska zyada asar padne ki ummeed hai.
Ek whistleblower letter mein yeh bhi alleged hai ki Union Bank of India ne Current Account Savings Account (CASA) figures ko inflate karne ke liye short-term deposits ka istemal kiya. Isse public sector banks mein reporting accuracy par sawaal uth rahe hain.
Market Ka Outlook
Market mein economic pressures aur sector opportunities ka yeh split shayad continue karega. Geopolitical events aur oil price fluctuations se short term mein Indian equities par pressure reh sakta hai. Lekin AI aur pharma sector mein jo interest hai, woh investors ke liye growth opportunities dikha raha hai.
Analysts ko lagta hai ki RBI ke regulatory actions, jaise ECL framework aur unsecured lending par pehle kiye gaye controls, banks ke risk assessment aur lending patterns mein changes layenge. Commodity investments vs. equities ka performance dekhte rehna hoga, jo investors ke risk appetite aur inflation hedging strategies ko indicate karega.